Who are Montelukast + Levocetirizine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/montelukast-levocetirizine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Montelukast + Levocetirizine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Montelukast + Levocetirizine (Montelukast + Levocetirizine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukotriene receptor antagonist + Selective H1-receptor antagonist. Area: Immunology / Allergy.

phase 3 Leukotriene receptor antagonist + Selective H1-receptor antagonist CysLT1 receptor (montelukast); H1 histamine receptor (levocetirizine) Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Montelukast + Levocetirizine (Montelukast + Levocetirizine) — Hanmi Pharmaceutical Company Limited. This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (levocetirizine) to reduce allergic inflammation and symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Montelukast + Levocetirizine TARGET	Montelukast + Levocetirizine	Hanmi Pharmaceutical Company Limited	phase 3	Leukotriene receptor antagonist + Selective H1-receptor antagonist	CysLT1 receptor (montelukast); H1 histamine receptor (levocetirizine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukotriene receptor antagonist + Selective H1-receptor antagonist class)

Hanmi Pharmaceutical Company Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Montelukast + Levocetirizine — Competitive Intelligence Brief. https://druglandscape.com/ci/montelukast-levocetirizine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab